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Efficacy, Safety, and Tolerance of Piperacillin/Tazobactam 
Compared to Co-Amoxiclav plus an Aminoglycoside 
in the Treatment of Severe Pneumonia 
R. Speich, E. Imhof, M. Vogt, M. Grossenbacher, W. Zimmerli 
Abstract An open, randomized, multicenter study was conducted to compare the 
efficacy and safety of piperacillin/tazobactam andco-amoxiclav plus aminoglycoside 
in the treatment of hospitalized patients with severe community-acquired or noso- 
comial pneumonia. Of the 89 patients who entered the study, 84 (94%) were clinical- 
ly evaluable. A favorable clinical response was observed in 90% of the piperacillin/ 
tazobactam group and in 84% of the co-amoxiclav/aminoglycoside group (not signif- 
icant). The bacteriological efficacy was comparable in both groups (96% vs. 92%; 
not significant). There was only one fatal outcome in the piperacillin/tazobactam 
group compared to six in the co-amoxiclav/aminoglycoside group regimen 
(P=0.058). The adverse vent rate was non-significantly lower in the piperacillin/ 
tazobactam group compared to the co-amoxiclav/aminoglycoside group (2% vs. 7%; 
P= 0.32). Piperacillin/tazobactam is safe and highly efficacious in the treatment of 
serious pneumonia in hospitalized patients. It compares favorably with the combina- 
tion of co-amoxiclav/aminoglycoside. 
Introduction 
Piperacillin is a semi-synthetic penicillin with a broad 
spectrum of antibacterial ctivity. Administered paren- 
terally, it has been widely used in the treatment of seri- 
ous infections, including pneumonia [1-3]. However, 
the growing prevalence of /3-1actamase-producing or- 
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ganisms increasingly imits the clinical efficacy of piper- 
acillin as monotherapy [4]. Tazobactam, a recently de- 
veloped penicillinic acid sulfone, irreversibly inhibits a 
wide range of bacterial/~-lactamases. Consequently, ta- 
zobactam prevents the inactivation of piperacillin by 
/3-1actamase-producing microorganisms such as Staphy- 
lococcus aureus, Haemophilus influenzae, Moraxella 
catarrhalis, Escherichia coli, Klebsiella pneumoniae, and 
anaerobes [5-7]. 
In two recent rials, the combination of piperacillin and 
tazobactam was effective, well tolerated, and safe in the 
treatment of hospitalized patients with pneumonia [8, 
9]. Furthermore, two randomized, comparative; multi- 
center trials indicate that piperacillin/tazobactam is as 
effective as cefuroxime and more effective than cefta- 
zidime in this same indication (A.P. Pallett and M.P. 
Carroll, 6th International Congress for Infectious Dis- 
eases, Prague, 1994, Abstract no. 857; M. Joshi et al., 
6th International Congress for Infectious Diseases, Pra- 
gue, 1994, Abstract no. 856). The present study was de- 
signed to compare the efficacy, tolerance, and safety of 
piperacillin/tazobactam with that of co-amoxiclav plus 
aminoglycoside in patients with serious community-ac- 
quired or nosocomial pneumonia. 
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Materials and methods 
Entry Criteria. Participants included patients of either sex -16  
years of age with pneumonia defined by the presence of three 
criteria: i) body temperature >38 ~ ii) new or progressive infil- 
trates on chest radiographs or focal signs on physical examination 
of the chest, and iii) at least two of the following: new onset of 
purulent sputum (_>25 leukocytes and _<10 epithelial cells per 
low power microscopical field) or signs of infection (elevated C- 
reactive protein, elevated erythrocyte sedimentation rate, leuko- 
cytosis); respiratory pathogen isolated from blood culture; isola- 
tion of pathogen from sputum or specimen obtained by bron- 
choalveolar lavage, bronchial brushing or biopsy. The severity of 
the changes on the initial chest radiographs was scored as follows: 
1, mild: unilobar infiltrates; 2, moderate: bilobar infiltrates; 3, se- 
vere: bilateral infiltrates. Only patients with at least one of the 
following criteria indicating nosocomial or serious infections were 
included: i) hospital-acquired infection (at least 48 h after admis- 
sion); ii) underlying disease (diabetes, alcoholism, chronic bron- 
chitis, collagen vascular disease); iii) the presence of at least two 
of the following clinical signs: diastolic blood pressure 
_< 60 mmHg; respiratory rate _> 30/min; PaO2-< 6.6 kPa. 
Exclusion criteria included known allergy to any of the study 
drugs; history of cystic fibrosis, tuberculosis, or respiratory tract 
carcinoma; antibiotic therapy within 12 h of enrollment; HIV in- 
fection; neutropenia (<1000/mm 3) or thrombopenia (<50000/ 
ram3); septic shock; hemodialysis, peritoneal dialysis, plasmapher- 
esis or hemoperfusion; elevated serum transaminases, alkaline 
phosphatase or bilirubin (>3 above the normal values); previous 
treatment with piperacillin/tazobactam or co-amoxiclav/aminogly- 
coside during the present hospital stay; pregnancy or breast feed- 
ing. 
Study Design. This open, randomized, comparative study was 
conducted in five hospital centers in Switzerland. Patients were 
randomized to receive ither piperacillin/tazobactam or co-amox- 
iclav/aminoglycoside n a 1:1 ratio according to a computer-de- 
rived program. Both regimens were administered as 30-rain i.v. 
infusions. The piperacillin/tazobactam reatment consisted of a 
combination of 4 g of piperacillin and 500 mg of tazobactam at8 h 
intervals, while the co-amoxiclav/aminoglycoside group received 
a combination of 2 g of amoxicillin and 200 mg of clavulanic acid 
at 8 h intervals, plus a single dose of 3-6 mg/kg of aminoglycoside 
(netilmicin or gentamicin). The patients were to be treated for a 
minimum of 48 h and a maximum of 21 days. 
Outcome Measures. During the period of antibiotic treatment, 
routine clinical evaluations were performed aily during the first 
week, and every 2 to 3 days thereafter. Laboratory parameters 
were determined on day 4 and on the last day of treatment. Bac- 
teriological cultures were repeated on day 4 and, if possible, at 
the cessation of the study, and all concomitant therapy was re- 
corded in detail. Ten to 14 days following the cessation of treat- 
ment, the patient's general status was assessed. 
The clinical response to therapy was classified as follows: non- 
assessable, <48 h of therapy; cure, clinical response with disap- 
pearance of fever, tachypnea, nd other clinical signs (except for 
chest x-ray) and symptoms during the treatment period; improve- 
ment, marked reduction of the signs and symptoms of infection, 
without complete resolution; relapse, adequate initial response 
followed by a worsening of the clinical condition due to the occur- 
rence of a bacterial or fungal infection within 7 days of stopping 
treatment; failure, no response to at least 48 h of antibiotic thera- 
py, worsening of the clinical condition due to infection, or 
death. 
The bacteriological efficacy was assessed in patients treated for at 
least 48 h and exhibiting one or more baseline pathogens accord- 
ing to the following classification: documented eradication, all ba- 
seline pathogens eradicated and no new pathogens present in fol- 
low-up cultures; presumed eradication, o repeat sputum sample 
could be obtained in a patient with a favorable clinical response; 
documented persistence, any baseline pathogen was present in a 
culture or cultures obtained from any site of infection upon com- 
pletion of therapy; presumed persistence, unfavorable clinical 
outcome, but no follow-up cultures were available; super-infec- 
tion, all baseline pathogens were eradicated, but one or more new 
pathogens appeared in the follow-up cultures; indeterminate, 
switch of antibiotic therapy, concomitant antibiotic therapy for 
reasons other than failure, death during therapy for a reason not 
related to the infection, or <48 h of therapy. 
All adverse vents occurring during the trial were recorded. The 
possible relationship of an adverse event to treatment was as- 
sessed as definite, probable, possible, remote, not related, or un- 
known. The safety analysis was performed on all patients who 
were enrolled in the study (intent-to-treat). 
Statistical Methods. All values are presented as the mean ---SD. 
Frequencies and categories were compared using Fisher's exact 
test. The Mann-Whitney U test was used for continuous variables. 
A P value < 0.05 was considered significant. 
Results 
Patient Characteristics. A total  of 89 pat ients were en- 
rol led: 44 in the p iperac i l l in / tazobactam group and 45 
in the co-amoxic lav/aminoglycos ide group. The two 
groups were highly comparab le  regarding demograph ic  
characterist ics,  cl inical signs, and laboratory  as well  as 
rad iographic  parameters  of severity of pneumonia  (Ta- 
ble 1). Ten pat ients had nosocomia l  pneumonia  and 79 
serious communi ty -acqu i red  pneumonia .  
Clinical Efficacy. For  the clinical efficacy evaluat ion,  
five pat ients had to be exc luded (3 in the piperaci l l in/  
tazobactam group and 2 in the co-amoxic lav/aminogly-  
coside group)  for the fol lowing reasons: t reatment  du- 
rat ion less than 48 h (n = 4), and er roneous inclusion of 
a pat ient  with ur inary tract infection (n = 1). The mean 
durat ion of ant ib iot ic  therapy in all pat ients was 10.2 
days for the p iperac i l l in / tazobactam group and 10.1 
days for the co-amoxic lav/aminoglycos ide group. In the 
cl inically evaluable  pat ients,  the mean durat ion of 
t reatment  was 10.7 days for the p iperac i l l in / tazobactam 
group and 10.5 days for the co-amoxic lav/aminoglyco-  
side group. 
The results of the clinical efficacy evaluat ion (84 pa- 
t ients) are presented in Table  2. Clinical cure was 
achieved in 33 (81%) of the pat ients t reated with piper-  
ac i l l in / tazobactam and in 28 (65%) of the pat ients who 
received co-amoxic lav/aminoglycos ide (P=0.091) .  An  
overal l  favorable cl inical response (cure or improve-  
ment)  was observed in 37 (90%) of the piperaci l l in/  
tazobactam pat ients and in 36 (84%) of the co-amoxi -  
c lav/aminoglycoside pat ients (P=0.288) .  There  were 
three (7%) t reatment  fai lures in the piperaci l l in/tazo-  
bactam group and six (14%) in the co-amoxic lav/ami-  
noglycoside group (P=0.266) .  One pat ient  in each 
group relapsed.  
Table I Demographic charac- 
teristics and clinical data at 
presentation f patients 
treated with either piperacil- 
lin/tazobactam or co-amoxi- 
clav/aminoglycoside 
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Characteristic PIP/TAZ group Co-AMX/amino group P value 
(n =44) (n =45) 
Age (years)* 64.7_+ 18.7 64.6 + 17.0 >0.5 
Nosocomial pneumonia 4/4 6/45 0.38 
Temperature (~ 38.9 + 0.8 38.6 + 0.9 0.11 
Leukocytes (109/1)* 13.7 + 6.1 15.0 + 6.6 0.48 
C-reactive protein (mg/1)* 185 +104 186 +125 >0.5 
Serum urea (mmol/1)* 12.2 + 25 17.1 + 39.1 0.47 
Albumin(g/I) 35 -+7 34 -+8 >0.5 
Radiographic score* 2.3 + 0.8 2.3 + 0.7 >0.5 
* Values expressed as mean + SD. 
PIP, piperacillin; TAZ, tazobactam; Co-AMX, co-amoxiclav; amino, aminoglycoside 
Table 2 Clinical efficacy in 




No. (%) of patients 
Outcome PIP/TAZ group Co-AMX/amino group P value 
(n =41) (n =43) 
Cure a 33 (81) 28 (65) 0.09 
Improvement b 4 (10) 8 (19) 0.2 
Relapse c 1 (2) 1 (2) >0.5 
Failure d 3 (7) 6 (12) 0.26 
a Clinical response with disappearance of fever, tachypnea, nd other clinical signs (except for chest 
x-ray) and symptoms during the treatment period. 
b Marked reduction of the signs and symptoms of infection, without complete resolution. 
~ Adequate initial response followed by a worsening of the clinical condition due to the occurrence 
of a bacterial or fungal infection within 7 days of stopping treatment. 
a No response to at least 48 h of antibiotic therapy, worsening of the clinical condition due to infec- 
tion, or death. 
PIP, piperacillin; TAZ, tazobactam; Co-AMX, co-amoxiclav; amino, aminoglycoside. 
Whereas there was one death in the piperacillin/tazo- 
bactam group, six deaths occurred among patients re- 
ceiving co-amoxiclav/aminoglycoside (P = 0.0586; 
P=0.0584 in the intent-to-treat analysis, which in- 
cluded all 89 patients). All causes of death were attri- 
butable to pneumonia, either due to respiratory failure, 
irreversible septic shock, or multiple organ failure. 
None of these deaths were attributed to the study med- 
ication. 
Bacteriological Efficacy. For the analysis of bacterio- 
logical efficacy, it was necessary to exclude 19 patients 
in the piperacill in/tazobactam group and 18 patients in 
the co-amoxiclav/aminoglycoside group. Bacteriologi- 
cal non-evaluability was due to the absence of a base- 
line pathogen (n =32), treatment duration of less than 
48h (n=4),  and incorrect diagnosis (n=l ) .  Bacteria 
were isolated in 25 of the 41 clinically evaluable pa- 
tients (61%) in the piperacill in/tazobactam group and 
in 27 of the 43 evaluable patients (63%) in the co- 
amoxiclav/aminoglycoside group. The majority of the 
patients were infected with a single pathogen; four pa- 
tients had two pathogens, and one patient had three. 
Streptococcus pneumoniae was the most common pa- 
thogen. It was isolated in 14 of the 25 (56%) piperacil- 
l in/tazobactam patients, and 13 of the 27 (48%) co- 
amoxiclav/aminoglycoside patients. The second most 
common pathogen was Haemophilus influenzae, which 
was detected in four patients in each group. Twenty 
other pathogens were identified: Staphylococcus aureus 
(n = 7), Escherichia coli (n = 3), Streptococcus pyogenes 
(n=3),  Haemophilus pp. (n=2) ,  Klebsiella oxytoca 
(n =2), Klebsiella pneumoniae (n = 1), Moraxella catar- 
rhalis (n = 1), and Streptococcus milleri (n = 1). 
Fourteen patients (32%) in the piperacill in/tazobactam 
group had positive blood cultures compared to 12 
(27%) in the co-amoxiclav/aminoglycoside group. 
Three patients in the piperacill in/tazobactam group and 
one in the co-amoxiclav/aminoglycoside group har- 
boured Staphylococcus epiderrnidis, which was consid- 
ered a contaminant. In all four cases there was heavy 
growth of respiratory pathogens in the sputum cultures: 
Streptococcus pneumoniae (n= 2), Moraxella catarrhalis 
(n = 1), and Haemophilus influenzae (n = 1). The 11 pi- 
peracill in/tazobactam patients with possibly true-posi- 
tive blood cultures harbored the following microorgan- 
isms: Streptococcus pneumoniae (n =8), Haernophilus 
influenzae (n = 1), Escherichia coli (n = 1), and Staphy- 
lococcus aureus (n=l ) .  The possibly true-positive 
blood cultures of the 11 aforementioned co-amoxiclav/ 
aminoglycoside patients grew the following microor- 
ganisms: Streptococcus pneurnoniae (n = 9), Streptococ- 
cus pyogenes (n = 1), and Klebsiella pneurnoniae (n = 1). 
Only one strain of Staphylococcus aureus in the pipera- 
cillin/tazobactam group was resistant to amoxicillin. 
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Table 3 Bacteriological effica- 
cy in evaluable patients 
treated with either piperacil- 
lin/tazobactam or co-amoxi- 
clav/aminoglycoside 
No. (%) of patients 
PIP/TAZ group Co-AMX/amino group P value 
(n =25) (n =27) 
Eradication (documented) 14 (56) 14 (52) 0.49 
Eradication (presumed) 10 (40) 11 (40) >0.5 
Indeterminate 1 (4) 0 0.48 
Persistence (documented) 0 1 (4) >0.5 
Persistence (presumed) 0 1 (4) >0.5 
PIP, piperacillin; TAZ, tazobactam; Co-AMX, co-amoxiclav; amino, aminoglycoside. 
Not unexpectedly, seven strains of Streptococcus pneu- 
moniae (1 in the piperacillin/tazobactam group and 6 in 
the co-amoxiclav/aminoglycoside group) were resistant 
to aminoglycosides. 
The bacteriological efficacy at cessation of antibacterial 
therapy in the 52 evaluable patients is shown in 
Table 3. A favorable bacteriological response (docu- 
mented or presumed eradication of the baseline pa- 
thogen) was observed in 24 of 25 (96%) evaluable pa- 
tients in the piperacillin/tazobactam group and in 25 of 
27 (92%) patients in the co-amoxiclav/aminoglycoside 
group (P=0.53). Persistence of the baseline pathogen 
at study cessation occurred in two patients in the co- 
amoxiclav/aminoglycoside group (both Klebsiella oxy- 
toca, 1 case documented and 1 presumed). 
Adverse Events. Four adverse vents were registered: 
one in the piperacillin/tazobactam group and three in 
the co-amoxiclav/aminoglycoside group (2% vs. 7%; 
P=0.32). The only adverse vent occurring in the pi- 
peracillin/tazobactam group - an elevated SGPT/ 
SGOT serum level - was considered to be possibly due 
to the antibacterial regimen. In the co-amoxiclav/ami- 
noglycoside group, acute renal failure (n = 2) and fever 
of 38.5 ~ (n =1) were considered to be remotely or 
possibly drug related. 
Discussion 
The results of the present trial indicate that piperacillin/ 
tazobactam is highly efficacious in the treatment of se- 
rious pneumonia in hospitalized patients. Its clinical ef- 
ficacy was at least as good as co-amoxiclav plus amino- 
glycoside. Whereas the clinical cure rate was slightly 
(but not significantly) higher in the piperacillin/tazo- 
bactam group (81%) compared to the co-amoxiclav/ 
aminoglycoside group (65%), the overall favorable re- 
sponse rate was equal with both regimens. Further- 
more, the piperacillin/tazobactam regimen was as good 
as the comparator therapy with respect o the eradica- 
tion of baseline pathogens. 
Interestingly, although the severity of the pneumonia 
was comparable in both patient groups (Table 1), the 
mortality was lower in the piperacillin/tazobactam 
(2.4%) than in the co-amoxiclav/aminoglycoside group 
(14%). The difference almost reached statistical signifi- 
cance (P = 0.059). Thus, the mortality rate in the piper- 
acillin/tazobactam group was quite low considering the 
fact that our study included only patients with serious 
pneumonia s defined in the Methods ection. The pos- 
sibly drug-related adverse vents were non-significantly 
lower with the piperacillin/tazobactam reatment (2%) 
than with the co-amoxiclav/aminoglycoside regimen 
(7%; P=0.32). 
Th  increasing prevalence of /3-1actamase-producing 
microbes has reduced the clinical efficacy of piperacil- 
lin as a monosubstance [4]. The association of the /3- 
lactamase inhibitor tazobactam with piperacillin res- 
tores the activity of the latter to a very considerable de- 
gree, as demonstrated by a number of trials [5-7] and 
by recent worldwide surveys indicating ood in vitro ac- 
tivity of this combination against gram-negative and 
gram-positive aerobic and anaerobic organisms (A.P. 
Pallett and M.P. Carroll, 6th International Congress for 
Infectious Diseases, Prague, 1994, Abstract no. 857; M. 
Joshi et al. 6th ICID, Prague, 1994, Abstract no. 856) 
[10-13]. The spectrum of activity of piperacillin/tazo- 
bactam extends to most pathogens encountered in se- 
vere bacterial pneumonia. This combination has recent- 
ly been investigated in two non-comparative trials in 
patients with mild to moderate pneumonia [8, 9]. In 
both of these studies, the combination therapy was 
found to be clinically and bacteriologically efficacious, 
well-tolerated and safe. The present rial provides evi- 
dence that this applies also to patients with serious 
pneumonia. Our results are in accordance with two oth- 
er randomized, comparative trials that have shown that, 
in this same indication, piperacillin/tazobactam is asef- 
fective as cefuroxime (A.P. Pallett and M.P. Carroll, 
6th ICID, Prague, 1994, Abstract no. 857), and more ef- 
fective than ceftazidime (M. Joshi et al., 6th ICID, Pra- 
gue, 1994, Abstract no. 856), regarding both clinical and 
microbial efficacy. 
In these trials the safety assessments of the piperacillin/ 
tazobactam association were also favorable, and the re- 
sults were independent of the co-administration f ami- 
noglycosides. These latter drugs are often administered 
in combination with other antibacterial substances for 
treatment of severe nosocomial infections. Their use is 
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associated with toxicity and increased costs for moni- 
toring drug serum levels and renal function. Therefore,  
the development of  equally effective combinations not 
containing aminoglycosides would be advantageous. 
The present study was designed to provide a direct 
compar ison between piperaci l l in/tazobactam and a 
standard drug combination, namely co-amoxiclav plus 
an aminoglycoside. Our  results indicate that the pipera- 
ci l l in/tazobactam combinat ion compares favorably with 
co-amoxiclav plus an aminoglycoside. Moreover,  costly 
monitor ing of renal function and drug serum levels are 
not required with the piperaci l l in/tazobactam treat- 
ment. 
In conclusion, the present clinical trial indicates that pi- 
peraci l l in/tazobactam is highly efficacious and safe for 
the treatment of serious pneumonia  in hospitalized pa- 
tients. It further demonstrates that this drug combina- 
tion compares favorably with that of co-amoxiclav plus 
an aminoglycoside. 
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